CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Congratulations to the PR22 Team Centre hospitalier universitaire de Sherbrooke who were recognized with the Phase III Team Award for Intergroup-Led Trials at the CCTG Spring Meeting. This award is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Congratulations to Dr. Anna Spreafico from Princess Margaret Cancer Centre (UHN) who received the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting.
We are very excited to announce that Nanthini Tharahan from the Princes Margaret Clinical Trials Support Unit has received the inaugural Excellence in Clinical Trials Conduct Award at the CCTG Spring Meeting. This award is presented to an individual who exemplifies excellence in clinical trial operations or compliance at their institution.
“I would like to express my sincere thanks for the award.”
CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated.
This study is being done to answer the following questions:
Request an invitation portal: closes April 17th
Online Registration: closes April 19th
On-site Registration: Beat the Friday morning line-up and register on Thursday!!
